Please assess the completion status of the following clinical trial:

Trial Title: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement, impairment of color vision)~* First episode of ADON~* Able to undergo treatment with IV steroids~Exclusion Criteria:~* History of any unexplained eye or neurological symptoms lasting longer than 48 hours~* Optic neuritis in both eyes~* Concomitant condition in either eye, other than optic neuritis~* History of heart condition/disease~* Patients with uncontrolled diabetes mellitus~* Patients with liver conditions/disease~* Inability to undergo MRI~* Pregnant or nursing women~* Women of childbearing potential who are not using highly effective method of birth control~  * Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5mg/daily (Type: EXPERIMENTAL): Oral capsule dose was given once daily for 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48

Based on this trial design, predict the completion outcome and termination type (if applicable).